BRPI0408961A - método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente - Google Patents

método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente

Info

Publication number
BRPI0408961A
BRPI0408961A BRPI0408961-8A BRPI0408961A BRPI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A BR PI0408961 A BRPI0408961 A BR PI0408961A
Authority
BR
Brazil
Prior art keywords
patient
determining
condition
erbb
cancer
Prior art date
Application number
BRPI0408961-8A
Other languages
English (en)
Inventor
Po-Ying Chan-Hui
Hossein Salimi-Moosavi
Yining Shi
Sharat Singh
Rajiv Dua
Ali Mukher-Jee
Sailaja Pidaparthi
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/623,057 external-priority patent/US7105308B2/en
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Publication of BRPI0408961A publication Critical patent/BRPI0408961A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO PARA DETERMINAR UMA SITUAçãO DE DOENçA DE UM PACIENTE, MéTODO PARA SELECIONAR UM PACIENTE PARA TRATAMENTO DE UM CáNCER COM UM OU MAIS MEDICAMENTOS DE AçãO DIMéRICA DE ERBB, E, MéTODO PARA DETERMINAR UMA SITUAçãO CANCEROSA DE UM PACIENTE". A invenção está direcionada a uma nova classe de biomarcador em amostras de paciente que compreende dímeros de receptores de membrana de superfície celular de ErbB. Em um aspecto, a invenção inclui um método para determinar uma situação de uma doença ou condição saudável correlacionando-se tal condição com as quantidades de um ou mais dímeros de receptores de membrana de superfície celular de ErbB medidas diretamente em uma amostra do paciente, em particular uma amostra de tecido fixa. Em um outro aspecto, a invenção inclui um método para determinar uma situação de um câncer em um espécime de um indivíduo correlacionando-se medições de quantidades de um ou mais dímeros de receptores de membrana de superfície celular de ErbB nas células do espécime para tal situação, incluindo a presença ou ausência de um estado pré canceroso, presença ou ausência de um estado canceroso, prognóstico de um câncer ou responsividade ao tratamento. Preferivelmente, os métodos da invenção são implementados usando-se conjuntos de compostos de ligação tendo rótulos moleculares liberáveis que são específicos para componentes múltiplos de um ou mais tipos de dímeros receptores. Depois da ligação, os rótulos moleculares são liberados e separados da mistura de ensaio para análise.
BRPI0408961-8A 2003-04-01 2004-03-30 método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente BRPI0408961A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45988803P 2003-04-01 2003-04-01
US10/623,057 US7105308B2 (en) 2002-07-25 2003-07-17 Detecting receptor oligomerization
US49448203P 2003-08-11 2003-08-11
US50803403P 2003-10-01 2003-10-01
US51294103P 2003-10-20 2003-10-20
US52325803P 2003-11-18 2003-11-18
PCT/US2004/009715 WO2004091384A2 (en) 2003-04-01 2004-03-30 Erbb surface receptor complexes as biomarkers

Publications (1)

Publication Number Publication Date
BRPI0408961A true BRPI0408961A (pt) 2006-10-31

Family

ID=33136354

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0408950-2A BRPI0408950A (pt) 2003-04-01 2004-03-30 método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica
BRPI0408961-8A BRPI0408961A (pt) 2003-04-01 2004-03-30 método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente
BRPI0408928-6A BRPI0408928A (pt) 2003-04-01 2004-03-30 métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0408950-2A BRPI0408950A (pt) 2003-04-01 2004-03-30 método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0408928-6A BRPI0408928A (pt) 2003-04-01 2004-03-30 métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente

Country Status (6)

Country Link
EP (3) EP1613205B1 (pt)
JP (2) JP2006523314A (pt)
AU (3) AU2004225439A1 (pt)
BR (3) BRPI0408950A (pt)
CA (3) CA2521106A1 (pt)
WO (3) WO2004087887A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
EP1613205B1 (en) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP5025724B2 (ja) * 2006-04-18 2012-09-12 ウェルスタット バイオロジクス コーポレイション 循環腫瘍性細胞からのタンパク質の検出
WO2008019375A2 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
EP2179291B1 (en) * 2007-07-13 2014-10-22 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
AU2009219437B2 (en) 2008-02-25 2014-10-16 Nestec S.A. Drug selection for breast cancer therapy using antibody-based arrays
US8168755B2 (en) * 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
WO2010019952A2 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
JP2012515353A (ja) * 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20140248291A1 (en) * 2011-03-30 2014-09-04 The Uab Research Foundation Modulation of Cellular Migration
EP2751562B1 (en) 2011-09-02 2015-09-16 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US20160041171A1 (en) * 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
JP6478417B2 (ja) * 2013-05-21 2019-03-06 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 大腸癌患者の生存を予測及び改善するための方法
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
US20190041389A1 (en) * 2015-02-13 2019-02-07 The University Of Queensland Methods for classifying tumors and uses therefor
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161030A1 (en) 2016-03-15 2017-09-21 Laboratory Corporation Of America Holdings Methods of assessing protein interactions between cells
JPWO2019098385A1 (ja) * 2017-11-20 2020-12-24 コニカミノルタ株式会社 薬剤評価方法
IT201800008274A1 (it) * 2018-08-31 2020-03-02 Alifax Srl Metodo immunometrico per analisi cliniche biologiche

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
CA2141451C (en) 1992-07-31 2003-10-07 John S. Pease Photoactivatable chemiluminescent matrices
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US6037134A (en) * 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US5693271A (en) 1994-09-01 1997-12-02 Chase Industries, Inc. Rotationally molding an insulated plastic molded door with integral hinge
US5599631A (en) 1995-03-08 1997-02-04 Eastman Kodak Company Fluorinated elastomer/fluorinated resin compositions for toner fusing members
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6095661A (en) 1998-03-19 2000-08-01 Ppt Vision, Inc. Method and apparatus for an L.E.D. flashlight
WO2000014105A1 (en) * 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
EP1305632B1 (en) 2000-05-04 2011-07-27 Siemens Healthcare Diagnostics Products GmbH Methods for detection of multiple analytes
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
WO2002068668A2 (en) * 2001-02-22 2002-09-06 Immunex Corporation Compositions and methods for production cell culture
CA2445053A1 (en) 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
AU2002316577A1 (en) 2001-07-09 2003-01-29 Aclara Biosciences, Inc. Cell-screening assay and composition
CA2354690A1 (en) 2001-07-20 2001-10-27 Jan Prinzmetal Mat
US6545102B1 (en) * 2001-09-27 2003-04-08 Lumigen, Inc. Polymer-supported photosensitizers
WO2003068808A1 (en) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Novel protein complexes and uses therefor
EP1654377A4 (en) * 2002-03-01 2010-03-24 Roger Williams Hospital PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER
JP2006509183A (ja) * 2002-03-05 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 膜結合増感剤を用いる多重分析
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP4443407B2 (ja) 2002-07-25 2010-03-31 アクララ バイオサイエンシーズ， インコーポレイテッド レセプターオリゴマー形成の検出
EP1613205B1 (en) * 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy

Also Published As

Publication number Publication date
CA2521077A1 (en) 2004-10-28
EP1613205A4 (en) 2006-11-29
AU2004225439A1 (en) 2004-10-14
WO2004091384A2 (en) 2004-10-28
EP1613961A2 (en) 2006-01-11
CA2521082A1 (en) 2004-10-28
WO2004087887A3 (en) 2006-06-15
EP1613205B1 (en) 2013-04-24
JP2006521821A (ja) 2006-09-28
AU2004230700A1 (en) 2004-10-28
CA2521106A1 (en) 2004-10-14
BRPI0408928A (pt) 2006-09-12
BRPI0408950A (pt) 2006-03-28
WO2004087887A2 (en) 2004-10-14
AU2004229348A1 (en) 2004-10-28
WO2004092353A3 (en) 2005-03-03
WO2004091384A3 (en) 2005-12-29
EP1613205A2 (en) 2006-01-11
EP1613961A4 (en) 2007-03-07
WO2004092353A2 (en) 2004-10-28
JP2006523314A (ja) 2006-10-12
EP1613732A4 (en) 2012-03-14
EP1613732A2 (en) 2006-01-11

Similar Documents

Publication Publication Date Title
BRPI0408961A (pt) método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente
Figueiredo et al. Genetic and epigenetic regulation of skeletal muscle ribosome biogenesis with exercise
Suo et al. Hydrogen sulfide prevents H2O2-induced senescence in human umbilical vein endothelial cells through SIRT1 activation
BRPI0412725A (pt) marcadores para detecção de cáncer gástrico
Kazemi et al. VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans
Lan et al. Progesterone, via yes‐associated protein, promotes cardiomyocyte proliferation and cardiac repair
Biederman et al. Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis
RU2008108907A (ru) Способ предсказания ответа на лечение
BRPI0413471A (pt) métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
Daniel et al. Transgelin is a marker of repopulating mesangial cells after injury and promotes their proliferation and migration
Ramage et al. NMDA receptor expression and activity in osteoarthritic human articular chondrocytes
Diel et al. Characterisation of the pharmacological profile of desoxymethyltestosterone (Madol), a steroid misused for doping
Nagano et al. The inhibitory effect of soybean and soybean isoflavone diets on 2, 4-dinitrofluorobenzene-induced contact hypersensitivity in mice
WO2021158720A1 (en) Disease detection and treatment based on phenylacetyl glutamine levels
Roesch et al. Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells
US7105292B2 (en) Screening methods used to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
Beetch et al. Subtle alterations in DNA methylation patterns in normal cells in response to dietary stilbenoids
Koizumi et al. Involvement of androgen receptor in nitric oxide production induced by icariin in human umbilical vein endothelial cells
Zhu et al. Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells
BRPI0315735B8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
Wiedswang et al. Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed
Vemani et al. Analysis of a Urinary Biomarker Hydroxyproline for Clinical Assessment in Osteoporosis Patients
Ohshima et al. bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts
Baur et al. GDF15 controls primary cilia morphology and function thereby affecting progenitor proliferation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A,4A,5A,6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.